RGNX
REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.15
+3.25%Oct 16, 2026, 11:02 UTC
REGENXBIO said Kenneth T. Mills will resign from its board of directors effective October 21, 2026, and George Migausky will become chairman of the board while Daniel Tassé becomes lead independent director.
Oct 12, 2026, 11:05 UTC
REGENXBIO announced that it will host an investor event on surabgene lomparvovec (Sura-vec) for wet age-related macular degeneration on October 20, including a clinical program overview and perspectives from retina specialists.
Source:Sep 24, 2026, 23:17 UTC
REGENXBIO presented positive three-year durability data from the Phase II ALTITUDE study of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy at the Retina Society Annual Scientific Meeting.
Source:Sep 23, 2026, 20:13 UTC
REGENXBIO Inc. signed a settlement agreement with Sarepta Therapeutics under which Sarepta will pay $39.0 million and all ongoing patent litigation over the Patents-in-Suit will be terminated, with a covenant not to sue over AAVrh74-based capsid products including ELEVIDYS.
Aug 25, 2026, 00:00 UTC
REGENXBIO Inc. appointed Gregory Ciongoli as a Class II director, effective August 25, 2026, and he will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
Aug 25, 2026, 00:00 UTC
A.N. "Jerry" Karabelas resigned as a director of REGENXBIO Inc., effective August 25, 2026.
Aug 25, 2026, 00:00 UTC
Jean Bennett resigned as a director of REGENXBIO Inc., effective August 25, 2026.
Aug 24, 2026, 11:25 UTC
The U.S. Food and Drug Administration placed a clinical hold on Regenxbio's experimental gene therapy for Hunter syndrome after spinal scans found abnormalities in five study participants.
Aug 6, 2026, 11:05 UTC
REGENXBIO reaffirmed the path forward for RGX-121 for Hunter syndrome with the FDA during a productive July Type A meeting, with resubmission on track for Q3 2026.
Aug 6, 2026, 11:05 UTC
REGENXBIO announced that its BLA submission for RGX-202 for Duchenne muscular dystrophy is on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027.
Source:Aug 6, 2026, 11:05 UTC
REGENXBIO announced that topline data from pivotal subretinal wet AMD studies, ATMOSPHERE and ASCENT, are expected in Q4 2026.
Source:Aug 6, 2026, 11:05 UTC
REGENXBIO raised over $200 million in new capital in July 2026, extending its cash runway into Q4 2027.
Source:Aug 6, 2026, 11:05 UTC
REGENXBIO reported its second quarter 2026 financial results and operational highlights.
Aug 6, 2026, 00:00 UTC
REGENXBIO Inc. received a $100 million milestone payment from AbbVie for the first patient dosing in the NAAVIGATE trial.
Source:Jul 20, 2026, 14:45 UTC
REGENXBIO Inc. announced long-term clinical trial results for its experimental gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) targeting wet age-related macular degeneration and diabetic retinopathy.
Source:Jul 16, 2026, 20:26 UTC
REGENXBIO Inc. announced a proposed public offering of $100 million of its common stock.
Source:Jun 29, 2026, 11:05 UTC
REGENXBIO dosed the first patient in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec for diabetic retinopathy.
Source:Jun 24, 2026, 11:55 UTC
The FDA agreed to reconsider a Hunter syndrome gene therapy that it had previously rejected.
Source:Jun 24, 2026, 11:55 UTC
Regenxbio will submit its Duchenne muscular dystrophy gene therapy for accelerated approval to the FDA.
Source:Jun 24, 2026, 11:05 UTC
REGENXBIO completed dosing in the confirmatory study of RGX-202, a gene therapy for Duchenne muscular dystrophy, marking completion of the registrational development program.
Source: